Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

92 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Lenalidomide Combination Therapy in Relapsed/Refractory Diffuse Large B Cell Lymphoma: The Italian Real-Life Experience.
Marangon M, Stefoni V, Castellino A, Visco C, Tani M, Cox MC, Marasca R, Tecchio C, Devizzi L, Monaco F, Romano A, Rusconi C, Rigacci L, Castellino C, Gaudio F, Argnani L, Zinzani PL. Marangon M, et al. Among authors: tecchio c. Clin Lymphoma Myeloma Leuk. 2019 Jul;19(7):e321-e323. doi: 10.1016/j.clml.2019.03.020. Epub 2019 Mar 29. Clin Lymphoma Myeloma Leuk. 2019. PMID: 31080169 No abstract available.
Estimated 6-year event-free survival of 55% in 60 consecutive adult acute lymphoblastic leukemia patients treated with an intensive phase II protocol based on high induction dose of daunorubicin.
Todeschini G, Tecchio C, Meneghini V, Pizzolo G, Veneri D, Zanotti R, Ricetti MM, Solero P, April F, Perona G. Todeschini G, et al. Among authors: tecchio c. Leukemia. 1998 Feb;12(2):144-9. doi: 10.1038/sj.leu.2400912. Leukemia. 1998. PMID: 9519775 Clinical Trial.
Rituximab, bendamustine and cytarabine (R-BAC) in patients with relapsed-refractory aggressive B-cell lymphoma.
Tisi MC, Paolini R, Piazza F, Ravelli E, Tecchio C, Sartori R, Famengo B, D'Amore ESG, Carli G, Perbellini O, Di Bona E, Ruggeri M, Visco C. Tisi MC, et al. Among authors: tecchio c. Am J Hematol. 2018 Dec;93(12):E386-E389. doi: 10.1002/ajh.25278. Epub 2018 Oct 9. Am J Hematol. 2018. PMID: 30184246 Free article. Clinical Trial. No abstract available.
Time to progression of mantle cell lymphoma after high-dose cytarabine-based regimens defines patients risk for death.
Visco C, Tisi MC, Evangelista A, Di Rocco A, Zoellner AK, Zilioli VR, Hohaus S, Sciarra R, Re A, Tecchio C, Chiappella A, Morello L, Gini G, Nassi L, Perrone T, Molinari AL, Fabbri A, Cox MC, Finolezzi E, Ferrero S, Puccini B, Alvarez De Celis I, Arcari A, Marino D, Merli M, Piazza F, Gentile M, Pelosini M, Loseto G, Hermine O, Dreyling M, Ruggeri M, Martelli M, Hoster E, Vitolo U; Fondazione Italiana Linfomi and the Mantle Cell Lymphoma Network. Visco C, et al. Among authors: tecchio c. Br J Haematol. 2019 Jun;185(5):940-944. doi: 10.1111/bjh.15643. Epub 2018 Nov 8. Br J Haematol. 2019. PMID: 30407625 Free article. No abstract available.
Lenalidomide in Pretreated Patients with Diffuse Large B-Cell Lymphoma: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice.
Broccoli A, Casadei B, Chiappella A, Visco C, Tani M, Cascavilla N, Conconi A, Balzarotti M, Cox MC, Marino D, Goldaniga MC, Marasca R, Tecchio C, Patti C, Musuraca G, Devizzi L, Monaco F, Romano A, Fama A, Zancanella M, Paolini R, Rigacci L, Castellino C, Gaudio F, Argnani L, Zinzani PL. Broccoli A, et al. Among authors: tecchio c. Oncologist. 2019 Sep;24(9):1246-1252. doi: 10.1634/theoncologist.2018-0603. Epub 2019 Apr 2. Oncologist. 2019. PMID: 30940746 Free PMC article.
MYC Rearranged Aggressive B-Cell Lymphomas: A Report on 100 Patients of the Fondazione Italiana Linfomi (FIL).
Tisi MC, Ferrero S, Dogliotti I, Tecchio C, Carli G, Novo M, Stefani PM, Rattotti S, Balzarotti M, Marino D, Pelosini M, Romano A, Flenghi L, Zilioli VR, Calimeri T, Di Napoli A, Zanni M, Finolezzi E, Mosna F, Gini G, Mansueto G, Di Rocco A, Tomei G, Sgherza N, Olivieri J, Nassi L, Piazza F, Fama A, Greco A, Giannoccaro M, Mazzone AM, Visco C, Loseto G, Zaja F. Tisi MC, et al. Among authors: tecchio c. Hemasphere. 2019 Oct 22;3(6):e305. doi: 10.1097/HS9.0000000000000305. eCollection 2019 Dec. Hemasphere. 2019. PMID: 31976479 Free PMC article.
Long-term results of the MCL01 phase II trial of rituximab plus HyperCVAD alternating with high-dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma.
Massaro F, Stepanishyna Y, Manni M, Luminari S, Galimberti S, Marcheselli L, Visco C, Tecchio C, Stelitano C, Angrilli F, Petrini M, Merli F, Federico M. Massaro F, et al. Among authors: tecchio c. Br J Haematol. 2021 Mar;192(6):1011-1014. doi: 10.1111/bjh.16714. Epub 2020 May 14. Br J Haematol. 2021. PMID: 32410259 Free article. Clinical Trial.
92 results